Patient Care

This page includes news coverage of various aspects of patient healthcare, including new technology innovations, what is working, what is not, personalized medicine and remote and telemedicine delivery. Find specific news in the areas of Care DeliveryDigital TransformationPrecision MedicineRemote Monitoring and Telehealth.

Google ups activity in 4 reaches of healthcare AI

Along with expanding research into large-language models to rival OpenAI’s ChatGPC, the search-engine king is working on AI for improving maternal care, ultrasound access and tuberculosis screening.

Thumbnail

Sanofi to acquire Provention Bio for $2.9B

Provention Bio's TZIELD is the first and only therapy to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. 

 

pain pills opioids

DOJ sues Rite Aid over role in opioid epidemic

According to the complaint, Rite Aid allegedly filled “at least” hundreds of thousands of unlawful prescriptions for controlled substances that lacked legitimate medical purpose, were not for a medically accepted indication or were not issued in the usual course of professional practice.

VA first to cover new ALZ drug

A new Alzheimer’s disease drug, Leqembi (lecanemab), will be covered by the Veterans Affairs for some patients, making the VA the first insurer to cover the drug.

To juice medical AI adoption, try a little Aristotelian persuasion

Wary consumers can be convinced to allow AI into their healthcare habits by communications campaigns tuned to the ancient rhetorical categories of ethos, pathos and logos. 

Thumbnail

Pfizer to acquire Seagen for $43B

“Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate technology with the scale and strength of Pfizer’s capabilities and expertise," says Pfizer Chairman and CEO Albert Bourla, PhD.

Hospital finance

More financial challenges ahead for not-for-profit hospitals

"Margins are not expected to return to pre-pandemic levels for quite some time," according to a new report.

Thumbnail

High costs limit the value of dapagliflozin, empagliflozin as heart failure treatments

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”